司美格鲁肽治疗肥胖及相关代谢性疾病的研究进展及临床挑战

中图分类号R977 文献标志码A 文章编号 1001-0408（2025）17-2205-06

DOI 10.6039/j.issn.1001-0408.2025.17.21

Researchprogressand clinicalchallengesof semaglutide inthe treatmentofobesityandrelated metabolic diseases

ZHANG Xinying1， ZHOU Yingying1，FU Xiaodan²， ZHANG Xianfeng²（1. Fourth Clinical Colege，Zhejiang ChineseMedical University，Hangzhou 310051，China;2.Dept.of Endocrinologyand Metabolism，Hangzhou First People's Hospital，Hangzhou 310006，China）

ABSTRACTAsanovellong-acting glucagon-likepeptide-1（GLP-1）receptoragonist，semaglutide playsa pivotalrole inthe treatentofobesityandrelatedmetabolicdiseases.Thisarticlesystematicallyreviewstheresearchprogressofsemaglutideinthe treatmentofobesityandrelatedmetabolicdiseases from three aspects：mechanismofaction，clinical aplications，andexisting challenges.Itisfoundthatitsmechanismofactioninvolvesmulti-organsynergisticregulationandmetabolicinterventionIts clinicalaplicationsencompassthetreatmentofobesitydiabetes，polycysticovarysyndrome，andliver-relatedmetabolic syndromes，anditdemonstratesgroundbreakingvalueincardiovascularandrenalprotection.However，itstllfacesmultiple challengesintsofdversereactios，indiidualiedtreatment，coomicaccesibilitythicalcotroversies，andssInte future，itisesentialtofurtheraccumulatelong-termsafetydataonsemaglutide，optimizecombinationtreatmentregimens，and addresskeyisuessuchasindividualizedmedicationforspecialpopulations，inodertofullrealizeitsclinicalapplicatiovalue.

KEYWORDSsemaglutide；glucagon-like peptide-1 receptor agonist；obesity；metabolic diseases；clinical challenges

根据世界卫生组织的分类标准，体重指数（bodymassindex，BMI） ⩾30kg/m2 的成年人被定义为肥胖[1-2]。（剩余17508字）